CLOs on the Move

VisuWell

www.visuwell.io

 
VisuWell is the leader in patient-centered, innovative, and affordable virtual care solutions. The VisuWell platform is an easy-to-use, enterprise-ready, browser-deployed technology increasing healthcare access for health systems, ambulatory care organizations, and payors. VisuWell offers patients and providers a comprehensive telehealth experience for consults, triage, telemedicine visits, and remote patient monitoring over a wide variety of use cases and environments. VisuWell enables care organizations to utilize their own provider networks to offer easy-to-access, high-quality care. The VisuWell platform creates a tailored virtual experience accommodating 35+ use cases serving thousands of locations and helping millions of people to see healthcare differently.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.visuwell.io
  • 1269 Market Street Suite 200
    Chattanooga, TN USA 37402
  • Phone: 888.220.4781

Executives

Name Title Contact Details

Similar Companies

Georgia Pediatric Pulmonology Associates

Georgia Pediatric Pulmonology Associates is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenstrief Institute

Regenstrief Institute, Inc., an international leader in electronic medical records and health care data integration, is a medical research and development organization focused on improving quality of care, efficiency of health care delivery, and enhancing patient outcomes.

Synvasive Technology Inc

Synvasive Technology Inc is a El Dorado Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Vireo Systems

At Vireo Systems we develop, manufacture and market products and brands that enhance the health of humans and animals. Our company is dedicated to maintaining excellence in all production processes and protecting the environment while delivering safe, ...